psychemdicslogo.jpg
Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen
October 27, 2023 11:00 ET | Psychemedics Corporation
Psychemedics debuts a 5-panel drug test replacing marijuana with fentanyl, the first hair drug test exclusively targeting the most dire workplace threats.
psychemdicslogo.jpg
Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer
September 21, 2023 17:00 ET | Psychemedics Corporation
ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon...
psychemdicslogo.jpg
Psychemedics Corporation Announces New Brazilian Distribution Agreement
September 19, 2019 17:25 ET | Psychemedics Corporation
ACTON, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A. and...
psychemdicslogo.jpg
Psychemedics Announces Second Quarter Results and Declares 92nd Consecutive Quarterly Dividend
July 23, 2019 17:25 ET | Psychemedics Corporation
ACTON, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2019.  The Company also announced...
ALERT: Rosen Law Firm Reminds Psychemedics Corporation Investors of Important Deadline in Class Action – PMD
March 13, 2017 17:53 ET | The Rosen Law Firm PA
NEW YORK, March 13, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Psychemedics Corporation securities (NASDAQ:PMD) from February 28, 2014 through...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Psychemedics Corporation – PMD
February 27, 2017 18:05 ET | The Rosen Law Firm PA
NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Psychemedics Corporation...